Profile data is unavailable for this security.
About the company
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
- Revenue in INR (TTM)8.14bn
- Net income in INR863.69m
- Incorporated1984
- Employees1.45k
- LocationGufic Biosciences Ltd1st to 4th Floor,S.M. House, 11 Sahakar Road,, Vile ParleMUMBAI 400057IndiaIND
- Phone+91 2 267261000
- Fax+91 2 267261067
- Websitehttp://gufic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Ltd | 17.73bn | 320.40m | 28.60bn | 5.93k | 93.03 | 2.63 | 20.98 | 1.61 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 30.54bn | 1.13k | -- | -- | 176.82 | 1.26 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 41.48bn | 1.27k | 44.93 | -- | 37.55 | 6.92 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 42.96bn | 2.16k | -- | 2.57 | -- | 3.52 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 43.37bn | 1.23k | -- | 137.18 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 43.77bn | 1.62k | 34.57 | -- | 29.25 | 2.51 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 43.97bn | 1.45k | 50.41 | -- | 42.50 | 5.40 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 44.19bn | 1.06k | 29.13 | 3.46 | 21.49 | 1.86 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Innova Captab Ltd | 11.42bn | 1.06bn | 44.50bn | -- | 32.82 | -- | 35.81 | 3.90 | 23.69 | 23.69 | 236.62 | -- | -- | -- | -- | -- | -- | 10.82 | -- | 18.38 | 33.38 | 25.18 | 9.30 | 8.04 | -- | 8.89 | -- | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 45.44bn | 1.20k | 853.41 | -- | 58.50 | 3.19 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Hikal Ltd | 18.03bn | 677.82m | 46.93bn | 2.06k | 69.28 | -- | 24.77 | 2.60 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Supriya Lifescience Ltd | 6.25bn | 1.58bn | 50.18bn | 448.00 | 31.91 | 5.54 | 28.71 | 8.03 | 19.54 | 19.54 | 77.55 | 112.56 | 0.6737 | 2.01 | 6.56 | 13,950,510.00 | 16.98 | 19.08 | 18.38 | 24.04 | 66.81 | 57.12 | 25.20 | 24.71 | 4.05 | 111.46 | 0.006 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Aarti Pharmalabs Ltd | 19.68bn | 2.28bn | 57.96bn | 1.63k | 25.41 | 3.12 | 18.88 | 2.95 | 25.16 | 25.16 | 217.12 | 204.88 | 0.7733 | 1.62 | 4.59 | 12,095,750.00 | 8.96 | -- | 11.86 | -- | 45.56 | -- | 11.59 | -- | 0.9611 | 17.12 | 0.1723 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Unichem Laboratories Ltd | 17.28bn | -605.50m | 58.55bn | 3.19k | -- | -- | 112.07 | 3.39 | -8.59 | -8.59 | 245.15 | -- | -- | -- | -- | 5,410,587.00 | -- | -1.67 | -- | -2.03 | 62.00 | 56.18 | -3.50 | -3.99 | -- | 0.1401 | -- | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
Data as of Nov 01 2024. Currency figures normalised to Gufic Biosciences Ltd's reporting currency: Indian Rupee INR
0.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 15 Oct 2024 | 423.74k | 0.42% |
| WhiteOak Capital Asset Management Ltd.as of 30 Sep 2024 | 54.30k | 0.05% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 27.06k | 0.03% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 22.88k | 0.02% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 5.91k | 0.01% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 5.03k | 0.01% |
| Bandhan AMC Ltd.as of 30 Sep 2024 | 356.00 | 0.00% |
| DFA Australia Ltd.as of 31 Aug 2024 | 82.00 | 0.00% |
| Groww Asset Management Ltd.as of 30 Sep 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
